Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II study.

被引：0
|
作者：
Fan, Li
Ye, Ting
Wang, Zhongliang
Cao, Rubo
Wang, Bicheng
Peng, Ling
Chen, Jing
机构：
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Whhan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24173
引用
收藏
页数：1
相关论文
共 31 条
  • [21] A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
    Hegg, Roberto
    Mattar, Andre
    de Matos-Neto, Joao Nunes
    Pedrini, Jose Luiz
    Aleixo, Sabina Bandeira
    Rocha, Roberto Odebrecht
    Cramer-Junior, Renato Peixoto
    van-Eyll-Rocha, Sylvie
    CLINICS, 2016, 71 (10) : 586 - 592
  • [22] Prospective, Randomized, Phase II, Non-Inferiority Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgery
    Minkowitz, Harold
    Navarro-Puerto, Jordi
    Lakshman, Shankar
    Singla, Sonia
    Cousar, Charles
    Kim, Robin
    Villavicencio, Alan
    Kirksey, Levester
    Ayguasanosa, Jaume
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (05) : 497 - +
  • [23] Evaluation of the Efficacy and Safety of DA-9601 versus Its New Formulation, DA-5204, in Patients with Gastritis: Phase III, Randomized, Double-Blind, Non-Inferiority Study
    Choi, Yoon Jin
    Lee, Dong Ho
    Choi, Myung-Gyu
    Lee, Sung Joon
    Kim, Sung Kook
    Song, Geun Am
    Rhee, Poong-Lyul
    Jung, Hwoon-Yong
    Kang, Dae-Hwan
    Lee, Yong Chan
    Lee, Si Hyung
    Choi, Suck Chei
    Shim, Ki-Nam
    Seol, Sang-Yong
    Moon, Jeong Seop
    Shin, Yong Woon
    Kim, Hyun-Soo
    Lee, Soo Teik
    Cho, Jin Woong
    Choi, Eun Kwang
    Lee, Oh Young
    Jang, Jin Seok
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2017, 32 (11) : 1807 - +
  • [24] Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
    Hua Ye
    Shengyun Liu
    Jian Xu
    Kexia Chai
    Dongyi He
    Yongfei Fang
    Qibing Xie
    Huaxiang Liu
    Ying Liu
    Bingzhu Hua
    Jiankang Hu
    Zhiyi Zhang
    Mingxuan Zhou
    Dongbao Zhao
    Yan Li
    Zhenyu Jiang
    Meimei Wang
    Jingyang Li
    Zhuoli Zhang
    Xiaomei Li
    Yang Li
    Erwei Sun
    Liqi Bi
    Wei Wei
    Ning Tie
    Lan He
    Xiangyang Huang
    Yan Zhang
    Qingchun Huang
    Xiaofei Wang
    Xiangyuan Liu
    Jing Li
    Yin Su
    Rheumatology and Therapy, 2023, 10 : 757 - 773
  • [25] Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
    Ye, Hua
    Liu, Shengyun
    Xu, Jian
    Chai, Kexia
    He, Dongyi
    Fang, Yongfei
    Xie, Qibing
    Liu, Huaxiang
    Liu, Ying
    Hua, Bingzhu
    Hu, Jiankang
    Zhang, Zhiyi
    Zhou, Mingxuan
    Zhao, Dongbao
    Li, Yan
    Jiang, Zhenyu
    Wang, Meimei
    Li, Jingyang
    Zhang, Zhuoli
    Li, Xiaomei
    Li, Yang
    Sun, Erwei
    Bi, Liqi
    Wei, Wei
    Tie, Ning
    He, Lan
    Huang, Xiangyang
    Zhang, Yan
    Huang, Qingchun
    Wang, Xiaofei
    Liu, Xiangyuan
    Li, Jing
    Su, Yin
    RHEUMATOLOGY AND THERAPY, 2023, 10 (03) : 757 - 773
  • [26] Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
    Mateos, Maria-Victoria
    Nahi, Hareth
    Legiec, Wojciech
    Grosicki, Sebastian
    Vorobyev, Vladimir
    Spicka, Ivan
    Hungria, Vania T. M.
    Korenkova, Sibirina
    Bahlis, Nizar J.
    Flogegard, Max
    Blade, Joan
    Moreau, Philippe
    Kaiser, Martin
    Iida, Shinsuke
    Laubach, Jacob
    Ahmadi, Tahamtan
    Parasrampuria, Dolly A.
    Peng, Lixian
    Qi, Ming
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
    Molina, Jean-Michel
    LaMarca, Anthony
    Andrade-Villanueva, Jaime
    Clotet, Bonaventura
    Clumeck, Nathan
    Liu, Ya-Pei
    Zhong, Lijie
    Margot, Nicolas
    Cheng, Andrew K.
    Chuck, Steven L.
    LANCET INFECTIOUS DISEASES, 2012, 12 (01): : 27 - 35
  • [28] Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study
    Tseng, Ling-Ming
    Chen, Fang Ming
    Chen, Shou-Tung
    Cheng, Fiona Tsui-Fen
    Chao, Tsu-Yi
    Dai, Ming-Shen
    Kao, Woei-Yau
    Yeh, Ming-Hsin
    Chen, Dar-Ren
    Liu, Liang-Chih
    Wang, Hewi Chung
    Chang, Hong-Tai
    Wang, Being Whey
    Yu, Jyh-Cherng
    Chen, Shin Cheh
    Liao, Guo-Shiou
    Hou, Ming-Feng
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (10) : 484 - 494
  • [29] Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study
    Mullasari, Ajit
    CARDIOLOGY AND THERAPY, 2020, 9 (02) : 505 - 521
  • [30] Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
    Giron-Hernandez, Cesar
    Han, Joong Hee
    Alberio, Roberta
    Singh, Arun
    Garcia-Portilla, Maria Paz
    Pompili, Maurizio
    Knight, R. Karl
    Richarz, Ute
    Gopal, Srihari
    Antunes, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 895 - 906
1234